EUVIMEDEUVIMED entdecken
Crossref

Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia

Ekaterina Ozhmegova iD, Aleksey Lebedev, Anastasiia Antonova, Anna Kuznetsova iD, Elena Kazennova, Kristina Kim, Aleksandr Tumanov, Marina Bobkova

HIV Medicine · 2024

DOI: 10.1111/hiv.13642 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2024. Verfasst von Ekaterina Ozhmegova und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Viral, Treatment Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to investigate mutations associated with, the causes of, and the conditions that contribute to HIV drug resistance (DR). This research provides crucial insights into the mechanisms through which HIV evades antiretroviral drugs and suggests strategies to counter this phenomenon. Our objective was to assess the prevalence and structure of DR in HIV‐1 across various regions in Russia and identify the primary factors influencing the development of HIV DR.

Methods

The study used nucleotide sequences from the HIV‐1 pol gene obtained from 1369 patients with a history of therapy and virological failure between 2005 and 2019 to analyze the frequency and structure of DR and the factors associated with it.

Results

The analysed HIV‐1 genotypes included viruses resistant to nucleoside reverse transcriptase inhibitors (NRTIs; 11.8%), non‐nucleoside reverse transcriptase inhibitors (NNRTIs; 6.4%), and NRTIs + NNRTIs (31.7%). The mutations M184V/I and G190A/S/E were the most prevalent, accounting for 54.5% and 26.6%, respectively. The dominance of multiple DR persisted throughout the entire observation period. The likelihood of encountering drug‐resistant variants was increased among men, patients in the late stage of infection, and those with a viral load

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Drug Resistance, ViralTreatment FailureHumansRussiaMaleFemaleAdultPrevalenceMiddle AgedMutationGenotypeAnti-HIV AgentsYoung AdultReverse Transcriptase InhibitorsViral Load

Stichwörter der Autor:innen

ARTHIV‐1drug resistancetreatment‐experienced patients

Substanzen

Anti-HIV AgentsReverse Transcriptase Inhibitors

Autor:innen und Institutionen

  • National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N. F. Gamaleya, Moscow, Russia.
  • I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia.

ORCID-Profile: Ekaterina Ozhmegova, Anna Kuznetsova

Förderung

  • Russian Science Foundation

Zitieren

APA

Ozhmegova, E., Lebedev, A., Antonova, A., Kuznetsova, A., Kazennova, E., Kim, K., Tumanov, A., & Bobkova, M. (2024). Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia. HIV Medicine. https://doi.org/10.1111/hiv.13642

Vancouver

Ozhmegova E, Lebedev A, Antonova A, Kuznetsova A, Kazennova E, Kim K, et al. Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia. HIV Medicine. 2024. doi:10.1111/hiv.13642

BibTeX
@article{Ozhmegova2024,
  author = {Ozhmegova, Ekaterina and Lebedev, Aleksey and Antonova, Anastasiia and Kuznetsova, Anna and Kazennova, Elena and Kim, Kristina and Tumanov, Aleksandr and Bobkova, Marina},
  title = {Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13642}
}
Kostenlos starten →